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A CRITICAL ROLE for tyrosine kinase signaling during cardioprotection has been demonstrated by multiple laboratories (1, 4, 6, 11, 14, 15) . Several studies have implicated the Src family of nonreceptor tyrosine kinases (6, 11, 15) ; however, many investigations have relied on pharmacological agents to demonstrate a role for these signaling elements. Thus the molecular identity of the specific nonreceptor tyrosine kinases involved in cardioprotection has remained elusive.
Proteomic analysis of myocardial PKC-⑀ complexes identified bone marrow tyrosine kinase gene in chromosome X (Bmx, also known as Etk), a member of the Tec/Btk family of nonreceptor tyrosine kinases, as a member of the PKC-⑀ subproteome (10) . Previous studies have implicated a role for the Tec family in proliferative and senescent cellular processes and, in particular, in mediation of signal transduction by cytokines, growth factors, and G protein-coupled receptors (8, 12) . Although one study documented expression of Bmx in the endocardium and the macrovascular endothelium (3), virtually nothing is known regarding the functional signaling role(s) of Bmx in the heart. Specifically, it is completely unknown 1) whether Bmx is activated by nitric oxide (NO) in the myocardium; 2) whether other nonreceptor tyrosine kinases, such as Bmx, form modules with PKC-⑀ in the heart; and 3) whether Bmx participates in cardioprotective signaling. To answer these questions, the expression and activation of Bmx were examined in a well-characterized rabbit model of NO donorinduced late preconditioning. The data indicate that Bmx was activated during protection and was resident in the PKC-⑀ complex, suggesting that this molecule may form a novel tyrosine kinase module with PKC-⑀. Given the known cardioprotective role of NO, these data have important implications regarding the ability of this ubiquitous signaling molecule to activate Tec kinases in the heart. Furthermore, the findings suggest a broader role for PKC-nonreceptor tyrosine kinase modules in the myocardium, which includes members outside the Src family.
METHODS
This study was performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 86-23).
Conscious rabbit model of diethylenetriamine-NO-induced late cardioprotection. A well-established conscious rabbit model of NOinduced cardioprotection was used as previously described (9, 15) . Briefly, male New Zealand White rabbits (2.0 -2.5 kg, 3-4 mo of age) were intravenously administered the NO donor diethylenetriamine (DETA)/NO (0.1 mg/kg once every 25 min for 75 min; total dose of 0.4 mg/kg). This dose of DETA/NO has been shown to activate PKC-⑀ and to induce a late phase of cardioprotection against infarction and stunning 24 h later (9, 15) . The PKC inhibitor chelerythrine (CHE; 5 mg/kg) was given 5 min before the first DETA/NO injection; this CHE dose has been shown to abolish NO-induced activation of PKC-⑀ and cardioprotection (9, 15) . Hearts were harvested either 30 min or 24 h after the last DETA/NO injection and and stored at Ϫ80°C until biochemical analyses were conducted.
Immunoprecipitation and Western blot analysis. Myocardial lysates were fractionated by differential centrifugation. Immunoprecipitation, SDS-PAGE, and immunoblotting were performed as previously described (9, 11, 15) . Antibodies to PKC-⑀ and Bmx and horseradish peroxidase-conjugated secondary antibodies were obtained from BD Transduction Laboratories. Values are means Ϯ SE. Groups were compared using Student's t-test for unpaired data. P Ͻ 0.05 was considered significant.
RESULTS AND DISCUSSION
Although previous investigations implicated a role for tyrosine kinases in PKC signaling during cardioprotection (1, 11, 14, 15) , characterization of the specific molecules involved is lacking. Several studies have demonstrated a role for Src family tyrosine kinases in cardioprotection (6, 11, 15) , but the importance of other nonreceptor tyrosine kinases is less well understood. In the present study, the nonreceptor tyrosine kinase Bmx was found to participate in PKC-⑀ signaling in a rabbit model of NO-induced cardioprotection. Taken with our previous study using a transgenic model of cardioprotection in the mouse (10) , this finding suggests that a cardioprotective role for Bmx may transcend model and species.
The present investigation demonstrates for the first time that exogenous NO donors activate Bmx in the myocardium, as evidenced by recruitment of Bmx to the particulate fraction. Importantly, the NO donor activated and increased the expression of Bmx concomitant with the late phase of cardioprotection afforded by the drug. Furthermore, the NO donor induced increased expression of Bmx via a PKC-dependent mechanism. These data suggest that a novel class of tyrosine kinases may form modules with PKC-⑀ during cardioprotection.
Translocation of Bmx is known to be indicative of activation, and association of Bmx with the membrane has been shown to occur through its lipid-binding plekstrin-homology domain (8, 12) . To determine whether Bmx participates in protective signaling systems of the heart, the subcellular distribution of this kinase was examined in the normal heart and after treatment with cardioprotective doses of the NO donor DETA/NO. Under basal conditions, the vast majority (90 Ϯ 9%; Fig. 1B ) of Bmx resided in the cytosol of the rabbit heart, in agreement with previous findings in other cell types (8, 12) . No translocation of Bmx was observed 30 min after administration of the NO donor (i.e., during the "trigger phase" of NO-induced protection), akin to what was observed for Src tyrosine kinase at this time (15) . In contrast to Src, however, the NO donor induced a significant increase in total expression of Bmx (128 Ϯ 2% of control; Fig. 1A) , concomitant with redistribution of Bmx to the particulate fraction 24 h later (38 Ϯ 3% in DETA/NO group vs. 10 Ϯ 1% in control group, P Ͼ 0.05; Fig. 1B ). This finding is particularly interesting, because translocation of Bmx, indicative of its activation (12) , occurred at the time at which the heart was protected against ischemic insult: 24 h after NO donor administration (i.e., during the "mediator phase" of NO-induced protection).
To examine whether activation of Bmx by NO in the heart was dependent on PKC, rabbits were pretreated with the PKC inhibitor CHE before they were preconditioned with the NO donor. Inhibition of PKC with CHE, at a dose previously shown to block the cardioprotective effects of ischemia-and NO-induced preconditioning (9) and, more recently, sildenafilinduced protection (2), blocked the increased expression (Fig.  1A) , but not translocation (Fig. 1B) , of Bmx observed in response to NO donor treatment. These data suggest that NO-induced Bmx expression and translocation are controlled by distinct mechanisms and that only the former is PKC dependent. In confirmation of our previous proteomic studies of PKC-⑀-mediated cardioprotection in the mouse, Bmx was found to localize to PKC-⑀ complexes (as detected by immunoprecipitation for PKC-⑀ followed by immunoblotting for Bmx) in the particulate, but not the cytosolic, fraction of the rabbit myocardium (Fig. 1C) .
It is important to note that although the ⑀-isoform of PKC has been shown to be protective in the mouse, studies from other species have implicated different isoforms of PKC in cardioprotection, for example, the ␣-isoform in dogs (7) and pigs (13) and the ␦-isoform in some forms of protection in rats (5) . Indeed, the species dependence of PKC isoform-specific signaling to Bmx and other Tec family kinases in the myocardium will be a key issue to resolve in future studies. At this point, the downstream tasks regulated by Bmx in cardioprotection are completely unknown. Previous studies have shown that Bmx activates STAT and NF-B in noncardiac cells (8, 12) . Therefore, these transcription factors, both of which have been shown to be necessary for cardioprotection, may be modulated by Bmx-dependent mechanisms in the heart. Furthermore, cross talk between Src and Bmx pathways and the role of Src in activation of Bmx [which has been documented in noncardiac cells (8, 12) ] remain to be determined in the setting of cardioprotection.
It has not escaped our attention that increased expression of a second, higher-molecular-weight species of Bmx is observed in the protected myocardium at 24 h (Fig. 1A) . The possibility exists that this second, higher-molecular-weight band is a posttranslationally modified species of Bmx. This modified species may represent an active, double tyrosine-phosphorylated form of Bmx, which is in agreement with previous investigations suggesting dual tyrosine phosphorylation as a mechanism to activate Tec kinases (8) . A second possibility would be a heretofore unrecognized serine/threonine phosphorylation of Bmx (in support of which, Bmx contains 9 putative PKC phosphorylation sites). The potential role of posttranslational modifications of Bmx in cardioprotective signal transduction is the focus of ongoing studies.
The present study is the first, to our knowledge, to report NO-dependent activation of the nonreceptor tyrosine kinase Bmx in the heart and to implicate a role for this kinase in cardioprotection. These findings are potentially important with regard to a greater understanding of PKC-tyrosine kinase modules in the heart.
